Introduction
Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac disease and has a prevalence of 2% in the general population. The widespread use of echocardiography and genetic screening for HCM has led to a growing number of young women diagnosed with HCM where most of them desire pregnancy. HCM in the nonpregnant state is associated with an increased risk of sudden cardiac death, arrhythmia, and heart failure and the pregnancy-associated changes in the cardiovascular system may exacerbate these risks, although their impact on maternal haemodynamics is not well understood. During pregnancy, there is an initial fall in peripheral vascular resistance occurring predominantly during the 1st and 2nd trimesters. This results in an increase in cardiac output of around 50% due to the combination of a greater stroke volume and higher heart rate. 1, 2 The increase in blood volume and consequently of left ventricular size offsets the adverse effect of the fall in peripheral vascular resistance on the LVOT gradient. In addition, enhanced LV contractility and higher heart rate with a shortened diastolic filling time, could exacerbate or precipitate heart failure and may not be well tolerated. Moreover, at the time of delivery, the auto-transfusion from the contracting uterus into the systemic circulation and stress related tachycardia during delivery and early postpartum, may lead to clinical deterioration. Despite these potential complications, it appears that most women with HCM tolerate pregnancy well. Previous studies report widely differing rates of cardiovascular complications, varying between 2 and 48%. However, most of the reports are retrospective or include small case series and may suffer from selection bias including more severe cases. [3] [4] [5] [6] [7] [8] This prospective study aims to provide information on the outcome of pregnancy in a cohort of pregnant women with HCM recruited to the observational, contemporary, worldwide Registry of Pregnancy and Cardiac disease (ROPAC). Such information may be helpful in pre-pregnancy counselling of women with HCM and identifying women at high-risk of an adverse outcome.
Methods
ROPAC is an ongoing prospective and worldwide registry initiated in 2007 by the European Society of Cardiology working groups on valvular heart disease and on congenital heart disease. 9 All consecutive pregnant women with structural heart disease, aortic pathology or pulmonary hypertension were included; non-structural heart diseases such as lone arrhythmic disease were excluded. Data were prospectively collected, and centres could also retrospectively include all consecutive patients up to 6 months before study entry. For this interim analysis, pregnancies in women with hypertrophic cardiomyopathy who were included in the study from 2007 up to 2014 were selected.
Data
The patient characteristics collected at baseline (before pregnancy) included age, ECG rhythm, diagnosis, risk factors for cardiovascular disease (smoking, diabetes, hypertension), previous interventions, medication, parity, obstetric history and facultative echocardiographic parameters. Follow-up was available for all patients up to 1 week after delivery; in addition follow-up at 6 months was available for part of the cohort. Patient characteristics and events were reported by the individual sites and did not undergo centralized adjudication. However, all events were predefined in the case report form.
Definitions
HCM was defined 'by the presence of increased left ventricular wall thickness that is not solely explained by abnormal loading conditions'. 10 The diagnosis HCM was confirmed if one or more left ventricular (LV) myocardial segments showed a thickness of > _15 mm on echocardiography, cardiac resonance imaging or computed tomography. Obstructive HCM was defined as 'an instantaneous peak Doppler LV outflow tract pressure gradient > _30 mm Hg at rest or during physiological provocation such as Valsalva maneuver, standing and exercise' (2014 ESC guidelines 10 ). These diagnostic features were confirmed in each patient by the local cardiologist. LVOT gradient was not collected as separate variable, and therefore could not be analysed.
The primary endpoint was a major adverse cardiovascular event (MACE), collected up to 1 week after delivery, including maternal death, heart failure (HF), thrombo-embolic events, and supraventricular or ventricular tachyarrhythmia. Heart failure was defined according to ACC/ AHA guidelines as a clinical syndrome that is characterized by specific symptoms (dyspnea and fatigue) and signs (of fluid retention, such as oedema, or rales) on physical examination as judged by the treating cardiologist. 11, 12 The heart failure episode was only registered when signs or symptoms of HF were present which required new treatment, change of treatment or hospital admission. A ventricular tachyarrhythmia (VTA) was defined as three or more consecutive ventricular beats with a mean rate of more than 100 beats per minute; however, only clinically relevant VTA (when the patient had physical complaints, needed treatment for VTA or when the patient had more than 100 consecutive beats) was included.
Other endpoints of interest were hospitalization for a cardiac reason, a Caesarean delivery for a cardiac reason, birth weight, small for gestational age (birth weight <10th percentile), miscarriage (<24 weeks), foetal death (> _24 weeks), neonatal death, termination of pregnancy, and preterm birth (<37 weeks). Baseline and outcome data were analysed for the total group; patients with and without MACE were compared and those with obstructive HCM compared with those with non-obstructive HCM.
Statistical analysis
Continuous variables are presented as mean and standard deviation, or as median and quartiles where appropriate. Differences were assessed with Student's t-test. Categorical variables are presented as percentages and differences were assessed using v 2 tests. Predictors of MACE were identified by performing univariable logistic regression analyses. The number of events (n = 15) did not allow for multivariable regression analysis. Statistical tests were considered significant if a p-value was less than 0.05 (two-sided). All analyses were performed using SPSS version 21.0 (IBM Corp., Armonk, NY).
Results
Sixty pregnancies in women with hypertrophic cardiomyopathy were included, from 28 centres in 19 countries; the majority were from countries with an advanced economy (n= 49, 81.7%). Mean age was 30.4 (±6.0) years and 30 (50.0%) were nulliparous. All pregnancies were singleton. Baseline characteristics are presented in had had an alcohol septal ablation, 1 patient surgical repair of the mitral valve had been performed, and in 3 patients there had been an unspecified intervention). In 4 patients (6.7%) an implantable cardioverter-defibrillator (ICD) was implanted. During pregnancy, 29 patients were treated with cardiac medication (48.3%); 24 were taking a beta-blocker (40.0%), five a calciumantagonist (8.3%), four diuretics (6.7%), and three antiarrhythmic medications (5.0%).
Maternal outcome
No maternal mortality occurred in this cohort. In 14 patients, at least one MACE occurred (23.3%, Figure 1 ); 9 developed HF (15.0%), 6 patients had a ventricular tachyarrhythmia (10%), and 1 patient had atrial fibrillation (1.7%). Two patients had two major adverse cardiac events: one developed both HF and ventricular tachycardia at 5 weeks of gestation and one developed HF at gestational age 23 weeks followed by a ventricular arrhythmia at 32 weeks. The timing of the first MACE was mainly in the 3rd trimester (n = 6) or postpartum (n = 4) ( Figure 1 ).
In Table 2 , the management of patients who suffered a MACE during pregnancy is presented. Before the event, four patients were taking a beta-blocker and in another four patients, a beta-blocker had been stopped. After the event, 9 of 14 started or continued a beta-blocker, in some in addition to diuretics or antiarrhythmic medication. One patient with a ventricular tachyarrhythmia in the 3rd trimester had an ICD implantation 2 days postpartum.
Results of the univariable analysis for MACE are shown in Table 3 . NYHA functional class of > _2 and signs of HF before pregnancy were significantly associated with MACE. The number of events was too small to allow for multivariable analysis. Two patients with heart failure also developed a ventricular arrhythmia.
Obstetric and foetal outcome
Pregnancy in women with hypertrophic cardiomyopathy Pregnancy duration in women with MACE was significantly shorter than in women without MACE. An emergency Caesarean delivery for a cardiac reason was performed in three of the 14 women with MACE: in 2 after HF (of whom one also had a ventricular tachyarrhythmia) and in 1 after atrial fibrillation. Five neonates (8.3%) were diagnosed with an inherited hypertrophic cardiomyopathy: 3 babies of women with non-obstructive HCM (8.6%) (in 1 of these 3, foetal loss at 23 weeks occurred), and 2 of the women with obstructive HCM (8.0%).
Obstructive and non-obstructive HCM No significant differences in pregnancy outcome were found between women with obstructive and non-obstructive HCM. The data are presented in Table 5 .
Follow-up
Follow-up at 6 months was available in 49 of the 60 pregnancies (81.7%) and no maternal mortality occurred during follow-up. One patient, with non-obstructive HCM and good LV function prior to pregnancy, was found to have severe LV dysfunction with apical thrombus formation-along with signs and symptoms of overt HFat 4 months after delivery with a gradual recovery of LV function after heart failure medication was started.
Discussion
The results of our study demonstrate a favourable maternal and foetal outcome in the majority of women with HCM who tolerated pregnancy well without maternal mortality. At the same time, however, 23% of the patient still developed important MACE including HF and arrhythmias. In addition, women with cardiac complications had a shorter duration of pregnancy and higher rates of emergency caesarean delivery. Functional status and signs of HF prior to pregnancy were associated with these complications.
Mortality in pregnant women with HCM
The results of this study support data obtained from few retrospective studies reporting low mortality rate (0%-2%) related to pregnancy in women with HCM. 5, 13, 14 . In the study by Autore et al.
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, 2 women (out of 100) with very high-risk profiles died during pregnancy. One had a septum thickness of more than 30 mm, a very high LVOT gradient and a poor functional class and the other had an extremely strong familial history of sudden death and had experienced prolonged runs of VT prior to death. A recent review presented the pooled analysis of 408 pregnancies including these two cases, which were the only deaths in the series, giving a maternal mortality rate of 0.5%. 15 It seems likely, if current recommendations 10 had been followed, that both of these deaths would have been prevented. Indeed, in our contemporaneous data, there was no maternal mortality, although at least 7 patients had a septal thickness of more than 30 mm.
MACE in pregnant women with HCM
A number of complications such as HF, arrhythmias, syncope, and thrombo-embolic complications have been described in women with HCM during pregnancy. The rates of these vary from 15% to 48% depending on the study design and patient population. 5, 7, 8, 15, 16 In our contemporary registry, almost a quarter of pregnant women with HCM developed either HF or arrhythmia and most of these complications occurred during the 3rd trimester or postpartum, consistent with the reported literature.
Heart failure and timing of occurrence
In our registry, 15% of women experienced HF, mainly during the 3rd trimester, but there was no difference in pregnancy outcome between women with obstructive and non-obstructive HCM. These data are consistent with two other studies where the presence of LVOT obstruction had no influence on maternal outcome. 6,7 Avila et al. 7 compared 12 non-pregnant and 23 pregnant women with HCM, and found that similar to our findings, 30% of pregnant women experienced HF mainly during the 3rd trimester. However, in the retrospective study by Autore et al. 5 HF symptoms tended to worsen more often in those with LVOT obstruction (25% vs. 11%), this difference however, was not statistically significant.
Arrhythmia
In our study we found that 11.7% of patients developed arrhythmia, 10% ventricular tachyarrhythmia, and 1.7% atrial fibrillation (1.7%). Avilla et al. 7 reported an arrhythmia rate of only 13% among 23 pregnant women with HCM, a rate lower than found in non-pregnant women with HCM and episodes of palpitations and arrhythmia during pregnancy in women with HCM which were similar to those experienced before their pregnancy. 6, 7 In contrast, in a retrospective review of 27 pregnancies in 23 women with HCM, Tanaka et al. 8 reported a cardiovascular event rate of 48%; the vast majority involved an arrhythmia and occurred during the 3rd trimester. In a series of 8 high risk women with HCM who had an implantable cardioverter defibrillator (ICD), 2 patients had VT (1 sustained and 1 non-sustained), and 2 had SVT. 17 Supporting our findings, Schinkel et al. in his recent review of the existing literature reported ventricular arrhythmias in 5% and supraventricular arrhythmias in 7% of the patients. 18 More information is needed in order to define the effect of pregnancy on the incidence and severity of arrhythmias in women with HCM.
Predictors of complications in pregnant women with HCM
Several studies reported that symptomatic women deteriorated more often during pregnancy than asymptomatic women with HCM. [6] [7] [8] In a large retrospective study (using questionnaires), Thaman et al. described 271 pregnancies in 127 women with HCM and found that the majority (90%) of women with symptoms during pregnancy had been symptomatic before. 8 Similarly, Autore et al.
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found that those who had symptoms prior to pregnancy were more likely to deteriorate then those who did not (42% vs. 4%). Tanaka et al. 8 identified the use of cardiac medication prior to pregnancy as a predictor of maternal complications in a retrospective study of 27 pregnancies in 23 women with HCM. In line with ESC risk stratification guidelines, 10 the results of our contemporary registry show that NYHA functional class of > _2 and signs of HF prior to pregnancy are associated with the occurrence of MACE.
In this registry, the most frequently observed foetal morbidity was premature birth (26%), followed by being small for gestational age (8%) and developing foetal bradycardia (3%). Another study described termination of pregnancy in 4 out of 27 pregnancies, all due to cardiovascular complications. 8 Pregnancy duration in this study in women with MACE was significantly shorter than in women without MACE and emergency Caesarean delivery for cardiac reasons was performed in 3 women, all of whom had a MACE. In a review of a large number of published cases Schinkel reported a 25% Caesarean section rate for predominantly obstetric indications and a 15% rate of spontaneous abortion 5% therapeutic abortions and a 2% stillbirth rate. 18 As in the current series, foetal mortality in all available reports is comparable with the general population 18 although it seems to occur mostly in women with cardiac complications, emphasizing the need for appropriate follow-up and management of women after a MACE, including close foetal monitoring.
Conclusions
Over the last decades, considerable progress has been made in the diagnostic evaluation, risk assessment, and clinical management in patients with HCM. Results of this contemporaneous, multicentre, prospective, worldwide registry showed that most women with HCM tolerated pregnancy well and there was no mortality. However, cardiovascular complications such as heart failure and arrhythmias were not uncommon and influenced foetal outcome and delivery. Functional status and signs of heart failure prior to pregnancy are important risk factors for cardiac complications in pregnant women with HCM. Pre-pregnancy counselling, close monitoring, and optimal care are mandatory to prevent complications in women with HCM.
Limitations
Our study has a number of limitations mostly related to missing information such as the LVOT gradient and its changes during pregnancy. However, obstructive HCM was defined as the presence of an LVOT gradient >30 mmHg, so we could characterize the group of women with obstructive HCM. In addition, there was incomplete information regarding family history, syncope and arrhythmias prior to pregnancy. In addition, a small number of women (13.8%) had a history of hypertension, which can cause LV hypertrophy leading to over diagnosis of HCM in some cases, unfortunately, the information on genetic testing is lacking in our registry. Despite these limitations, this prospective registry included a large number of women with HCM, managed according to contemporary guidelines, providing important information related to the maternal and foetal outcome in women with HCM.
